ttr-46 Antibody

Monoclonal Antibodies Targeting TTR in Amyloidosis

The search results highlight several antibodies under investigation for TTR amyloidosis treatment. Key examples include:

Table 1: Antibodies Targeting TTR in Clinical Development

(A) RT24 Antibody

• Epitope Specificity: Recognizes residues 118–122 of TTR, a cryptic epitope exposed in misfolded or aggregated TTR .

• Functional Activity:

  • Inhibits TTR fibrillization in a concentration-dependent manner .

  • Promotes macrophage-mediated phagocytosis of TTR fibrils .

  • Reduces TTR deposits in animal models of familial amyloid polyneuropathy (FAP) .

(B) ALXN-2220 (NI006)

• Clinical Progress: Currently in Phase 3 trials for ATTR cardiomyopathy (NCT06183931, NCT04622046) .

• Mechanism: Binds fibril-specific residues 41–45, enabling immune clearance without disrupting native TTR tetramers .

(C) Unnamed Antibody (George et al.)

• Demonstrated rapid amyloid clearance in experimental wild-type ATTR models .

• Developed a diagnostic ELISA to quantify aggregated TTR in patient sera .

Gaps in Current Data

The term "ttr-46 Antibody" does not appear in peer-reviewed publications, clinical trial registries, or preclinical datasets within the provided sources. Potential explanations include:

1. Nomenclature Variability: The antibody may be referenced under an alternative name (e.g., internal codes like NI301A for ALXN-2220).

2. Emerging Research: The compound could be in early-stage development without public disclosures.

3. Terminology Error: Possible typographical or transcriptional error in the query (e.g., "ttr-46" vs. "TTR-41–45" or "Coramitug").

Recommendations for Further Investigation

• Validate the antibody’s nomenclature with regulatory databases (e.g., ClinicalTrials.gov, WHO International Nonproprietary Names).

• Explore patent filings or industry pipelines for undisclosed TTR-targeting antibodies.

• Cross-reference with epitope regions (e.g., residues 41–45, 89–97, 115–124) to identify alignment with known candidates.